Payment overview · 2025
General Payments
$2,691.48
128 reported records · 25 companies
Healthcare provider profile · identity verified
Michael John Leser, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · YORK, PA · NPI 1568697258
Verified facts
What the public records show
CMS Open Payments records show Michael John Leser, D.O. received $2,691.48 in general payments during 2025 across 128 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $530.23 | 19.7% | 24 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $526.01 | 19.5% | 26 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.85 | 9.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $243.23 | 9.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.88 | 5.2% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $113.54 | 4.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.32 | 3.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $74.05 | 2.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $70.68 | 2.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $67.49 | 2.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.95 | 2.4% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $64.09 | 2.4% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $63.11 | 2.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $55.51 | 2.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.53 | 2.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.75 | 2.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.06 | 1.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.75 | 1.1% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $26.11 | 1.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.16 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.00 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.75 | 0.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.83 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.77 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.83 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,648.98 | 127 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $457.87 | 22 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $308.25 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $240.43 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $183.54 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $178.62 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $111.07 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.22 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.49 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $90.19 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $86.81 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $84.91 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $74.05 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.45 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $70.68 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.95 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $64.09 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $63.11 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.69 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.60 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $55.51 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $54.53 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.45 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.66 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.84 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 409 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
409 | 70 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
409 | 70 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1218 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 745 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 659 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 610 | 118 |
| Furosemide | Furosemide | 593 | 89 |
| Omeprazole | Omeprazole | 543 | 100 |
| Quetiapine Fumarate | Quetiapine Fumarate | 485 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 454 | 72 |
| Lisinopril | Lisinopril | 453 | 97 |
| Eliquis | Apixaban | 409 | 70 |
| Losartan Potassium | Losartan Potassium | 390 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 321 | 43 |
| Memantine Hcl | Memantine Hcl | 317 | 50 |
| Sertraline Hcl | Sertraline Hcl | 314 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 71 |
| Simvastatin | Simvastatin | 265 | 68 |
| Gabapentin | Gabapentin | 263 | 45 |
| Donepezil Hcl | Donepezil Hcl | 259 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 241 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 47 |
| Metformin Hcl | Metformin Hcl | 231 | 58 |
| Potassium Chloride | Potassium Chloride | 206 | 32 |
| Mirtazapine | Mirtazapine | 201 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 194 | 31 |
| Famotidine | Famotidine | 186 | 46 |
| Trazodone Hcl | Trazodone Hcl | 182 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 162 | 12 |
| Spironolactone | Spironolactone | 143 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 20 |
| Buspirone Hcl | Buspirone Hcl | 131 | 23 |
| Lorazepam | Lorazepam | 126 | 52 |
| Carvedilol | Carvedilol | 120 | 24 |
| Divalproex Sodium | Divalproex Sodium | 119 | 15 |
| Nifedipine Er | Nifedipine | 119 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 119 | 31 |
| Allopurinol | Allopurinol | 118 | 31 |
| Benztropine Mesylate | Benztropine Mesylate | 112 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 112 | 13 |
| Prednisone | Prednisone | 111 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 19 |
| Ezetimibe | Ezetimibe | 102 | 25 |
| Farxiga | Dapagliflozin Propanediol | 101 | 27 |
| Jardiance | Empagliflozin | 99 | 15 |
| Finasteride | Finasteride | 98 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 14 |
| Propranolol Hcl | Propranolol Hcl | 91 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 90 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 24 |
| Metformin Hcl Er | Metformin Hcl | 85 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 20 |
| Latanoprost | Latanoprost | 82 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 13 |
| Azithromycin | Azithromycin | 80 | 69 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 80 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 11 |
| Cephalexin | Cephalexin | 76 | 43 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 71 | 18 |
| Loperamide | Loperamide Hcl | 71 | 25 |
| Olanzapine | Olanzapine | 68 | 12 |
| Myrbetriq | Mirabegron | 67 | 11 |
| Pregabalin | Pregabalin | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 13 |
| Lamotrigine | Lamotrigine | 65 | suppressed |
| Risperidone | Risperidone | 65 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 33 |
| Xarelto | Rivaroxaban | 63 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 52 |
| Bupropion Xl | Bupropion Hcl | 59 | 19 |
| Digoxin | Digoxin | 58 | suppressed |
| Januvia | Sitagliptin Phosphate | 57 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 55 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 12 |
| Meloxicam | Meloxicam | 54 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Novolog Flexpen | Insulin Aspart | 53 | 11 |
| Atenolol | Atenolol | 52 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 52 | suppressed |
| Gemtesa | Vibegron | 52 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 52 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Tradjenta | Linagliptin | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | 13 |
| Alprazolam | Alprazolam | 43 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 35 |
| Nystatin | Nystatin | 41 | 19 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 15 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Moxifloxacin | Moxifloxacin Hcl | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 29 | 17 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | 11 |
| Glipizide Er | Glipizide | 23 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Cholestyramine Light | Cholestyramine | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Epogen | Epoetin Alfa | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 12 |
| Lumigan | Bimatoprost | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 14 |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,691.48 · 128 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, FANAPT, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, INCEPTIV, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OPSYNVI, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error